Note: Descriptions are shown in the official language in which they were submitted.
CA 02792136 2012-09-05
W02011/117333 1 PCT/EP2011/054511
REVERSE MICELLE SYSTEM COMPRISING
METAL IONS AND USE THEREOF
FIELD OF THE INVENTION
The present invention relates to reverse micelle system based on sterols,
acylglycerols, phospholipids
or sphingolipids and metal ions. Reverse micelle system of the invention is
able to cross mucosa and
cellular membranes. It thus allows vectorization of metal ions to target
sites. It is advantageously
useful in the pharmaceutical and dietetic fields.
BACKGROUND OF THE INVENTION
Over the last years, various approaches have been proposed to improve the
delivery of drugs at the
target site. First, the drug must be administered by a suitable and easy
route, such as orally or rectally,
and second the active ingredient must be delivered at the target cells under
an active form. There is no
device currently available allowing such a vectorized transport of active
molecules.
Many publications and patents describe methods for encapsulating active
ingredients into nano or
micro-particles, but the issue, to date unsolved, is to provide both an easy
route of administration
different from the injectable route, such as oral and buccal routes, and an
efficient delivery of the
active product at the target sites.
The inventors have previously uncovered that stirring two types of lipids with
some metallic salts
allowed to increase salt bioavailability and consequently to obtain same
therapeutic activity with 1000
to 5000 times lower doses ; the potential toxicity of said salts could then be
reduced [see US
6,129,924, WO 02/36134 and WO 2004/075990, for instance].
The inventors in particular identified novel products indicated under the term
"organometallic
complexes", and obtained by reaction between a derivative of vanadium in
oxidation state 4 or 5 and
two organic compounds isolated from plant extracts and respectively
constituted of sitosterol and
acylglycerols.
The inventors also discovered that similar complexes could be prepared from
other derivatives of
metals wherein the metal is for instance known for its antidiabctic activity.
They also discovered that similar complexes could be obtained from the organic
derivatives mentioned
previously and various cations of metals useful as biocatalysts in living
metabolism, these complexes
being particularly effective agents as vectors of said cations. Such
vectorization of metallic cations
affords an important decrease of the toxicity of administered cations compared
to their administration
CA 02792136 2012-09-05
WO 2011/117333 2 PCT/EP2011/054511
in the absence of micelles as previously described. Actually, the use of such
complexes, as described
in W02006/048773, allows efficient vectorization of the cations to target
sites and thus allows
administration of far lower amounts of metal. For instance, the use of these
complexes affords
obtaining the same therapeutic activity with 1000 to 10000 times lower doses.
Such complexes have been shown effective to vectorize metallic cations in
small quantities, for
instance lower than 80 lig of lithium, per ml of formulation. If such amounts
are sufficient to compare
the therapeutic activity of cations in animals, transposition to the human
scale requires higher amounts
of cations to be administered. The stability of microcmulsions containing
higher quantities of metal is
not always satisfactory to allow their development as delivery systems for
drugs and/or dietetic
compounds for example.
Incorporation of a phospholipid or a sphingolipid, in particular in specific
amounts, in the formulation
of microcmulsions comprising higher doses of metal ions surprisingly triggered
an important increase
in their stability.
The present invention describes new microemulsions formulations able to
vectorize high quantities of
metal ions, process of preparation and use thereof as delivery systems for
drugs and/or dietetic
compounds. "High" amounts refer here to amounts sufficient to obtain a
therapeutic activity at the
human scale, but that remain far lower than the amounts of cations delivered
in absence of complexes.
The reverse micelle system of the present invention may for instance allow
vectorization of up to 1500
lig of metal per ml of formulation.
This formulation advantageously renders possible the control and optimisation
of the composition
comprising micelles for their uses in the pharmaceutical and dietetic fields.
SUMMARY OF THE INVENTION
The present invention relates to a mucosally applied delivery system for the
release of metal ions as
well as the compositions and methods for preparing the delivery system. Herein
described are reverse
micelle systems designed to reach this goal in a safe and controlled manner.
The reverse micelle
systems are able to be absorbed through mucosa and to vectorize metallic
cations under a protected
form to any tissue of the organism.
The reverse micelles of the invention comprise more specifically at least one
metal ion, a sterol, an
acylglycerol, a phospholipid or a sphingolipid, an alcohol, and water.
The reverse micelles can be prepared according to a method described below
using at least a sterol, an
acylglyccrol, a phospholipid or a sphingolipid, an alcohol and water.
3
Said micelles are more particularly obtainable by the following method:
a) Contacting (i) sterol, preferably sitosterol or cholesterol, (ii)
acylglycerol, preferably
diacylglycerol, (iii) phospholipid, preferably phosphatidylcholine, or
sphingolipid, (iv)
alcohol, (v) water, preferably purified water, and (vi) at least one metal
ion,
b) Stirring mixture obtained in step (a), at 40 C or less, and for a time
sufficient to obtain
formation of reverse micelles.
The parameters of stirring, for instance duration and speed of mechanical
stirring, can be
readily determined by any one skilled in the art and depend on experimental
conditions. In
practice, these parameters are such that a microemulsion is obtained; the
speed is determined
so as to enable formation of a visually limpid formulation, and duration of
the stirring is such
that the stirring may be stopped a few minutes after obtaining the visually
limpid formulation.
The present invention further relates to a composition comprising reverse
micelles of the
invention and a pharmaceutically acceptable carrier, excipient or support.
According to another aspect, the present disclosure relates to a reverse
micelle system
comprising at least one metal ion, a sterol, an acylglycerol, a phospholipid
or a sphingolipid,
an alcohol and water, wherein the weight ratio phospholipid or
sphingolipid/acylglycerol is
from 0.05 to 0.40, and wherein acylglycerol presents the following formula
(I):
CH2ORi
CHOR2
CH2OR3 (I)
in which: R1 is an acyl residue of a linear or branched, saturated or
unsaturated fatty acid
having between 14 and 24 carbon atoms, an hydrogen atom, or a mono-, di- or
tri-galactose or
glucose ; R2 is an acyl residue of a linear or branched, saturated or
unsaturated fatty acid
having between 2 and 18 carbon atoms; R3 is an acyl residue of a linear or
branched, saturated
or unsaturated fatty acid having between 14 and 24 carbon atoms, or an
hydrogen atom.
DETAILED DESCRIPTION OF THE INVENTION
The following description is of preferred embodiments by way of examples only
and without
limitation to the combination of features necessary for implementing the
invention.
CA 2792136 2018-07-25
3a
Reverse micelles
The reverse micelle system according to the invention is characterized as a
microemulsion
comprising a dispersion of water-nanodroplets in oil. The dispersion is
stabilised by two
surfactants (acylglycerol, more preferably a diacylglycerol and a
phospholipid, more
preferably phosphatidylcholine, or a sphingolipid) and a co-surfactant
(alcohol) that are most
likely at the water/oil interface. The reverse micelle phase can be defined as
a system wherein
water forms the internal phase and the hydrophobic tails of the lipids form
the continuous
phase. Reverse micelles containing oil(s), surfactant(s), co- surfactant(s),
and an aqueous phase
are also characterized as water-in-oil microemulsions. These microemulsions
are
thermodynamically stable and visually limpid.
Generally, the size of micelles according to the invention is very small, more
particularly, it is
less than 10 nm; more specifically it is less than 8 nm and more preferably
less than 6 nm. The
size may vary with the quantity of added water and phospholipid or
sphingolipid. The present
invention relates more particularly to reverse micelles with an aqueous core
of around 4 nm,
preferably 3 to 5 nm, more preferably from 3.5 to 5 nm, in particular from 3.7
to 4.5 nm.
CA 2792136 2018-07-25
CA 02792136 2012-09-05
WO 2011/117333 4 PCT/EP2011/054511
The reverse micelles and the size of their aqueous core can be characterized
by various methods,
including:
- Small Angle X-Ray Scattering (SAXS)
- Neutrons Scattering
- Transmission Electron Microscopy (TEM)
- Dynamic Light Scattering (DLS)
The ratios of the lipidic constituents (including sterol, acylglycerol and
phospholipid or sphingolipid)
in the reverse micelle system according to the invention can vary. For
instance, the weight ratio
sterol/acylglycerol can range from 0.015 to 0.05, more particularly from 0.03
to 0.04. The weight ratio
phospholipid or sphingolipid/acylglyccrol can range from 0.05 to 0.40, in
particular from 0.06 to 0.25.
The weight of phospholipid or sphingolipids respectively corresponds to the
total weight of the
mixture of phospholipids or sphingolipids, for instance the weight of
lecithin, used in the formulation.
Similarly, the weight of acylgylycerol corresponds to the total weight of the
mixture usually
containing an acylglycerol, or a mixture of acylglycerols, with glycerol and
fatty acids derived from
said acylglycerol(s).
The compounds of the reverse micelle system can be analyzed by appropriate
means. More
specifically, sterols can be identified by gas chromatographic analysis and
acylglyccrol by high-
performance liquid chromatography (HPLC), in particular with a light
scattering detector, on a silica
column, in the presence of an eluent, e.g. isocratic acetonitrile. Gas
chromatography can also be used
to analyze diacylglycerols. Phospholipids and sphingolipids can be analyzed by
high-performance
liquid chromatography (HPLC), with a diol column with a light scattering
detector.
Reverse micelles are dynamic systems. Brownian motion causes perpetual
collisions of micelles,
which lead to coalescence of micelles and exchange of the aqueous cores.
Separation and regeneration
of micelles occur and allow chemical reactions between different solutions.
The exchange rate
between micelles increases in particular with temperature, the length of
hydrocarbon chains of the
surfactant, and the ratio water/surfactant. Within the context of the
invention, aqueous cores of
micelles must have a specific size allowing metal ions to be stabilised in the
prepared micelles. As
mentioned above, the size of the aqueous core is preferably around 4 nm, more
preferably from 3 to 5
nm, more specifically from 3.5 to 5 nm, in particular from 3.7 to 4.5 nm.
Reverse micelles may exist in the system of the invention as different
structural organizations, such as
spheres, cylinders or branched cylinders for instance.
Without being bound to any theory, it seems that inclusion of a phospholipid
or a sphingolipid, in
particular in specific amounts, in the reverse micelle system allows formation
of micelles with greater
CA 02792136 2012-09-05
WO 2011/117333 5 PCT/EP2011/054511
diameter and volume, thus allowing vectorization of greater amounts of metal
ions. This increase in
vectorized cations amounts affords vectorization of sufficient amounts to
obtain a therapeutic activity
in human.
The reverse micelle system of the invention ensures absorption of the
compounds to be delivered
across mucosa, preferably across mouth, nasal and/or rectal mucosa, more
preferably across mouth
mucosa. Also, reverse micelles of the present invention provide an important
bioavailability with low
variability of absorption.
Method for preparing reverse micelles
In a particular embodiment, the invention relates to a method for preparing
reverse micelles presenting
an aqueous core of around 4 urn, preferably from 3 to 5 urn, more preferably
from 3.5 to 5 nm, in
particular from 3.7 to 4.5 nm and involving at least one metal ion, a sterol,
an acylglycerol, a
phospholipid or a sphingolipid, an alcohol, and water, wherein said method
comprises the following
steps:
(a) Contacting (i) sterol, (ii) acylglycerol, preferably diacylglycerol, (iii)
phospholipid, preferably
phosphatidylcholine, or sphingolipid, (iv) alcohol, (v) water, preferably
purified water, and
(vi) at least one metal ion,
(b) Stirring mixture obtained in step (a), at 40 C or less, and for a time
sufficient to obtain
formation of reverse micelles.
The obtained and recovered reverse micelles are then particularly useful as a
delivery system for metal
ions. Step (b) of the process is of particular importance since it allows
reverse micelles to be obtained,
said reverse micelles being then useful as a transport system for delivering
metal ions at target sites.
Target sites may for instance be cells of a specific tissue.
In a particular embodiment, the metal ion is first solubilised in water
(preferably purified water) to
form an aqueous mixture. Said aqueous mixture is then introduced into the oily
mixture (step(a)). Said
oily mixture preferably comprises at least a sterol, an acylglycerol, a
phospholipid or a sphingolipid
and an alcohol.
The compounds involved in step (a) will be described in more details below.
Stirring of the mixture obtained by step (a) is carried out at a temperature
less than or equal to 40 C,
specifically ranging from 15 C to 40 C, or from 25 C to 40 C, or more
specifically from 30 C to 37
C. The time sufficient can vary in particular upon the used stirring
technique. The time of stirring is
anyhow the time needed to convert the initial mixture into a visually limpid
reverse micelle solution.
CA 02792136 2012-09-05
WO 2011/117333 6 PCT/EP2011/054511
One skilled in the art knows how to select excipicnts or components that may
be used along with the
composition according to the present invention in order to keep their
beneficial properties. In
particular, the presence of glycerol can, when introduced in large amount,
prevent the foimation of
reverse micelles or break the reverse micelle system. More specifically, no
more than 2.5% (percent
expressed by weight of glycerol / weight of acylglycerol) is used for the
preparation of the reverse
micelles of the present invention.
Other compounds can be introduced in step (a). One can cite for instance
colouring agents and/or
flavouring substances.
In an advantageous manner, the compounds cited above or the commercially
available mixtures
containing them are the only ingredients introduced to prepare the micelle
system and consequently
the only ones present in the micelle system of the invention.
Stirring of step (b) may for instance be performed by mechanical stirring.
The common materials may be propellers whose fast movements generate
turbulences and swirls
allowing interpenetration of particles and formation of reverse micelles
within the mixture.
Mechanical stirring speed is preferably ranging from 100 to 2 000 r/minute,
more preferably from 300
to 700 r/minutc. The implemented volumes, device, and stirring speed depend on
and should be
adapted with the reactants and amounts thereof
As described above, temperature of the mixture should not exceed 40 C as to
avoid degradation of the
reactants. Temperature is more specifically ranging from 15 C to 40 C, or from
25 C to 40 C, or
even more specifically from 30 C to 37 C.
REVERSE MICELLES COMPOUNDS
ACYLGLYCEROL
Acylglycerols useful for the preparation of the reverse micelle system
according to the invention can
be isolated from the majority of animals and more preferably plants.
Acylglycerols include mono- di and triacylglycerols. In a particular
embodiment, acylglycerols
preferentially used in the present invention present the following formula
(I):
CA 02792136 2012-09-05
WO 2011/117333 7 PCT/EP2011/054511
CH2ORi
CHOR2
CH2OR3
(I)
in which:
- Rt is an acyl residue of a linear or branched, saturated or unsaturated
fatty acid having between 14
and 24 carbon atoms, a hydrogen atom, or a mono-, di- or tri-galactose or
glucose;
- R, is an acyl residue of a linear or branched, saturated or unsaturated
fatty acid having between 2 and
18 carbon atoms;
- R3 is an acyl residue of a linear or branched, saturated or unsaturated
fatty acid having between 14
and 24 carbon atoms, or a hydrogen atom.
According to a particular embodiment, R1 or R3, preferably only one of R1 and
R;, in particular only
RI, represents an acyl residue of oleic acid (C18: l[cis]-9).
According to a particular aspect, R2 has one unsaturated bond (e.g; ethylenic
bond) and has
advantageously 18 carbon atoms, preferably R2 is an oleic acid residue (oleoyl
group), one of its
positional isomers with respect to the double bond (cis-6,7,9,11 and 13) or
one of its iso-branched
isomers.
According to another particular aspect, R1 represents an oleoyl group.
According to another particular aspect, R2 represents an acetyl group.
According to another particular aspect, Ri is a hydrogen atom.
As a general rule, oil containing a high concentration of oleic acid will be
chosen as a useful source of
acylglycerols according to the invention. Such oil usually contains a high
proportion of acylglycerols
useful according to the invention.
According to a particular aspect of the invention, the preferred diglyccrols
of fatty acids are selected in
the group consisting of 1,2-dioleoylglycerol (or also named herein 1,2-
diolein) and 1-oleoyl-2-acetyl
glycerol.
A certain number of them, and more particularly those which are found to be
the most active in the
applications sought after, are also available commercially. This is the case
particularly for 1-oleoyl-2-
CA 02792136 2012-09-05
WO 2011/117333 8 PCT/EP2011/054511
acctylglyccrol and 1,2-diolcoylglyccrol. Glycerol monoolcatc 40 contains about
33 % of diolcoyl
glycerol, and about 11% of 1,2-diolein and is pharmaceutically accepted
(European Pharmacopeia (41h
Edition), USP 25/NF20, and Japanese Standard of food Additives). Such product
is for instance
commercially available by Gattefosse Company under the name PECEOL .
The acylglycerols are preferably incorporated or comprised in the composition
or reverse micelle
system in an amount by weight ranging from 50 g to 90 g with respect to 100 g
of the total weight of
the composition or reverse micelle system according to the invention. The
amounts specified herein
will be adapted with respect to the other compounds as to correspond more
specifically to the weight
ratios identified below.
STEROLS
The sterols useful for the preparation of the reverse micelle system according
to the invention are
preferably natural sterols, such as cholesterol or phytosterols (vegetable
sterols). Sitosterol and
cholesterol are the preferred sterols useful for the reverse micelle system
according to the invention.
Sitosterol and cholesterol are commercially available. More particularly,
commercial sitosterol which
is extracted from soya can be used. In such a product, the sitosterol
generally represents from 50 to 80
% by weight of the product and is generally found in a mixture with
campesterol and sitostanol in
respective proportions in the order of 15% each. Commercial sitosterol which
is extracted from a
variety of pine called tall oil can also be used. In general, it will be
possible to use sitosterol in mixture
with sitostanol. Preferably, said mixture comprises at least 50% sitosterol by
weight of the mixture.
As mentioned above, the ratios of the lipidic constituents (sterols,
acylglycerol and phospholipids or
sphingolipids) in the reverse micelle system according to the invention can
vary. Preferably, the
weight ratio steroFacylglycerol can range from 0.015 to 0.05, more
particularly from 0.03 to 0.04. The
weight of sterol corresponds in the present invention to the total weight of
sterols used in the
formulation, for instance the weight of phytosterol.
The sterols are preferably incorporated or comprised in the composition or
reverse micelle system in
an amount by weight ranging from 0.825 g to 4.5 g with respect to 100 g of the
total weight of the
composition or reverse micelle system according to the invention. The amounts
specified herein will
be adapted with respect to the other compounds as to correspond more
specifically to the weight ratios
identified above and/or below.
CA 02792136 2012-09-05
WO 2011/117333 9 PCT/EP2011/054511
PHOSPHOLIPIDS AND SPHINGOLIPIDS
Phospholipids are formed of a glycerol linked to 2 fatty acids and to a
phosphate group. The variability
of phospholipids relies on the fatty acids that are attached to the glycerol
and on the chemical groups
that are susceptible to link to the phosphate group. Phospholipids are, with
sphingolipids, the major
lipidic constituents of biological membranes.
Among phospholipids useful in the present invention may be cited
phosphatidylethanolamine,
phosphatidylserine, phosphatidylglycerol, diphosphatidylglycerol,
phosphatidylinositol, and
phosphatidylcholine.
In a particular embodiment, the phospholipid is phosphatidylcholine.
Phosphatidylcholine is also
known as 1,2-diacyl-glycero-3-phosphocholine or PtdCho.
Phosphatidylcholine is formed from a choline, a phosphate group, a glycerol
and two fatty acids. It is
actually a group of molecules, wherein the fatty acid compositions varies from
one molecule to
another. Phosphatidylcholine may be obtained from commercial lecithin that
contains
phosphatidylcholine in weight concentrations of 20 to 98%. The lecithin
preferably used for the
preparation of the reverse micelles according to the invention is Epikuron 200
and contains
phosphatidylcholine at a concentration of more than 90%.
Sphingolipids are a class of lipids derived from the aliphatic amino alcohol
sphingosine. Among
sphingolipids that may be used in the present invention may be cited
acylsphingosin, sphingomyelins,
glycosphingolipids, and gangliosides.
The reverse micelles system of the invention may comprise phospholipids,
sphingolipids, or a mixture
of both types of compounds.
According to a specific embodiment, the reverse micelles system of the
invention comprises
phospholipids.
The weight ratio phospholipid and/or sphingolipid/acylglycerol in compositions
or reverse micelle
systems according to the invention is from 0.05 to 0.40, preferably from 0.06
to 0.25.
The phospholipids or sphingolipids are preferably incorporated or comprised in
the composition or
reverse micelle system in an amount by weight ranging from 1 g to 30 g,
preferably from 5 to 20 g
with respect to 100 g of the total weight of the composition or reverse
micelle system according to the
invention. The amounts specified herein will be adapted with respect to the
other compounds as to
correspond more specifically to the weight ratios identified above.
CA 02792136 2012-09-05
WO 2011/117333 10 PCT/EP2011/054511
ALCOHOLS
The alcohols useful for the preparation of the reverse-micelle system
according to the invention are
preferably linear or branched mono-alcohols from C2 to C6. Examples of
alcohols are ethanol, 1-
butanol, 2-butanol, 3-methyl-1-butanol, 2-methyl-1-propanol, 1-pentanol, 1-
propanol, 2-propanol and
any mixture thereof In a particular embodiment of the invention, alcohol is
ethanol.
The alcohol is preferably incorporated or comprised in the composition or
reverse micelle systems in
an amount by weight ranging from 5 g to 12 g with respect to 100 g of the
total weight of the
composition or reverse micelle system according to the invention.
WATER
The water useful for the preparation of the reverse micelle system according
to the invention is
preferably purified water.
Water is preferably incorporated or comprised in the composition or reverse
micelle systems in an
amount by weight ranging from 1 g to 15 g, preferably from 5 g to 15 g, with
respect to 100 ml of the
total volume of the composition or reverse micelle system according to the
invention.
One of ordinary skill in the art will adapt the amount of phospholipid or
sphingolipid in the systems to
the desired amount of water. For instance, increasing amount of water should
imply increasing amount
of phospholipid or sphingolipid in the systems.
METAL
Metal cations which may be used for preparing reverse micelle system according
to the invention are
any cation in an oxidation state of at least 1, and whose biocatalytic
activity is known or remains to be
discovered.
In the context of the present invention, the term "biocatalyst" will indicate
these metals exert a
catalytic activity on the biological systems.
Metal ions play an essential role in approximately a third of the enzymes
(Metal Ions in Biological
Systems, Jenny P.Glusker, Amy K.Katz and Charles W.Bock, The Rigaku Journal,
vol 16, N 2, 1999).
They can have different types of actions:
- modification of flows of electrons from the substrate or the enzyme,
allowing the control of an
enzymatic catalytic reaction,
CA 02792136 2012-09-05
WO 2011/117333 11 PCT/EP2011/054511
- connection with the proteinic components of the enzyme to give it a space
configuration
allowing it to present its active sites,
- to allow an activity of oxidation-reduction when metal has several
valences.
Metal will be selected according to the desired biological activity.
As examples, if a product is sought with hypolipidacmic activity, or
hypoglycaemic and/or anti-
diabetic and/or insulinomimetic activity, a metallic derivative of vanadium,
niobium, molybdenum,
selenium, chromium, zinc or titanium may more particularly be chosen.
As examples, if a product is sought with neuroprotective activity, a metallic
derivative of lithium may
more particularly be chosen.
As examples, if a product is sought with an activity on oxidative stress, a
metallic derivative of
manganese may more particularly be chosen.
As examples, if a product is sought with an activity on osteoporosis, a
metallic derivative of strontium
may more particularly be chosen.
As examples, if a product is sought with an activity on cancers, in particular
acute promyelocytic
.. leukemia, a metallic derivative of arsenic may more particularly be chosen.
In these metal derivatives:
- lithium is preferably in an oxidation state equal to 1,
- vanadium is advantageously in an oxidation state equal to 3, 4 or 5,
preferably 4,
- manganese is in general in an oxidation state comprised between and 1 and
7, preferably 2, 3,
4, 6 or 7,
- selenium is advantageously in an oxidation state equal to 4 or 6,
preferably 4,
- molybdenum is in general in an oxidation state comprised between 3 and 6,
preferably 3,
- chromium is preferably in an oxidation state equal to 3,
- niobium is advantageously in an oxidation state equal to 4 or 5,
preferably 5,
- arsenic is preferably in an oxidation state equal to 3,
- zinc is preferably in an oxidation state equal to 2, 3 or 4.
In a particular embodiment, the metal ion presents an oxidation state of at
least 1.
CA 02792136 2012-09-05
WO 2011/117333 12 PCT/EP2011/054511
Examples of metals adapted to other types of activity are indicated below:
- lithium in pathologies of the central nervous system, such as bipolar
disorder,
neurodegenerative diseases like Huntington's disease, Parkinson disease,
Alzheimer disease,
amyotrophic lateral sclerosis, multiple sclerosis, prevention of dementia, or
disease due to a
prion infection,
- antimony or tin, if the treatment of autoimnnme diseases concerning, in
particular, the nervous
system, for example multiple sclerosis and cancerology, is desired,
- gold, in autoimmune diseases affecting the locomotor system, for example
in rhumatoid
arthritis,
- vanadium in diabetes type 2, insulin resistance and metabolic syndrome,
- ruthenium or palladium in respiratory tumors or neoplasias,
- tin, in acquired immunodeficiency syndroms,
- selenium in cancerology,
- strontium in osteoporosis,
- arsenic in cancers, in particular acute promyelocytic leukemia,
- manganese in disease linked to oxidative stress.
In a particular embodiment, the metal cation is selected in the group
consisting of lithium, zinc,
niobium, vanadium, selenium, molybdenum, chromium, antimony, tin, gold,
ruthenium, palladium,
platinum, strontium, arsenic, and manganese.
Metal ions may be introduced in the reverse micelles of the invention as metal
salts.
By way of examples, particularly useful metal derivatives according to the
invention are selected from
sulphates, hydrates, halides, in particular chlorides, citrates, carbonates
and any other water-soluble
salt.
It will be possible in some cases to use ammonium salts, methoxides of alkali
metals or alkaline earth
metals which can be dissolved in water or sometimes in alcohols. However water-
soluble salts will be
preferred.
Any metal having a water-soluble salt can be introduced into the reverse
micelles according to the
invention. The choice of metal will vary upon the desired therapeutic
activity.
CA 02792136 2012-09-05
WO 2011/117333 13 PCT/EP2011/054511
Anyone skilled in the art is aware of the inherent difficulties of the
therapeutic use of metal cations
due to the toxicity of said metal cations in an effective active amount: well-
known examples are the
lithium salts used in psychiatric or neurologic disorder or the platinum,
ruthenium or palladium salts
used in cancerology. Inclusion of such cations in reverse micelle systems of
the invention allows using
the cations in low amounts.
As indicated above, a preferred metal is a metal exhibiting a biocatalytic
activity.
Since metal ions according to the invention can be delivered efficiently to
the target site(s),the
therapeutic activity is obtained with amounts of metal divided by 100 to 1 000
compared to the
activity obtained with a salt or an organic derivative of the same metal when
not included in the
reverse micelle system of the invention.
The weight concentration of the cations in the microemulsion is more
specifically calculated with a
density of 0.94 0.03 for the microemulsion.
The density is generally measured at room temperature and atmospheric
pressure.
REVERSE MICELLE SYSTEM AND USE THEREOF
The reverse micelles of the invention allow the metal ions included therein to
be administered and
transported to target sites, in particular cells.
It is known today that a reverse micelle system can be used for the
preparation of nanomaterials,
which act as micro reactors. The activity and stability of bio molecules can
be controlled, mainly by
the concentration of water in the reverse micelle system.
An object of the invention concerns a pharmaceutical composition comprising
reverse micelles as
defined above and at least a pharmaceutically acceptable carrier, excipient or
support.
According to a specific embodiment, the pharmaceutical composition according
to the invention
comprises from 5 to 20 g of phospholipid or sphingolipid with respect to 100 g
of composition, and
from 5 to 15 g of water with respect to 100 ml of composition.
In a specific embodiment, the pharmaceutical composition of the invention is
used for the delivery,
more specifically the mucosal delivery, of metal ions.
According to particular embodiments, the pharmaceutical composition is in the
form of a capsule, a
caplet, an aerosol, a spray, a solution or a soft elastic gelatin capsule. A
further object of the invention
CA 02792136 2012-09-05
WO 2011/117333 14 PCT/EP2011/054511
concerns the use of reverse micelles as defined above for preparing a
pharmaceutical composition
intended for the delivery, more specifically the mucosal delivery, of metal
ions.
Another object of the invention concerns a method for the delivery of at least
one metal ion to a
mammal (in particular human), said method comprising administering the reverse
micelle composition
as defined above to the mammal. In a specific embodiment, the present
invention provides a method
for the mucosal delivery of at least one metal ion, said method comprising
mucosally administering to
said mammal (in particular human) a reverse micelle composition as defined
above.
The present invention provides a method for the prevention, treatment, or
improvement of chronic
diseases. In a specific embodiment, the present invention provides a method
for the prevention,
treatment or improvement of one or more symptoms associated with a disease or
disorder in relation
with the catalytic activity of the used metal ion, said method comprising
mucosally administering to a
subject in need thereof an effective amount of a reverse micelle composition
as defined above and
comprising at least one metal ion useful in the prevention, treatment or
improvement of one or more
symptoms associated with said disease or disorder.
As pharmaceutically acceptable excipient, vehicle or carrier, any excipient,
vehicle or carrier well-
known to the person skilled in the art may be used. Other additives well-known
to the person skilled in
the art such as stabilisers, drying agents, binders or pH buffers may also be
used. Preferred excipients
in accordance with the invention promote adherence of the finished product to
the mucosa.
The present invention further concerns the use of a pharmaceutical composition
as described above for
the delivery of at least one metal ion to a mammal, said delivery comprising
mucosa administration of
the pharmaceutical composition.
The compositions of the invention can be administered in different ways, in
particular via mucosal
tissue absorption, with a buccal, nasal, vaginal or digestive absorption..
Pharmaceutical compositions as described above may be used in particular for
the prevention,
treatment or improvement of the symptoms of a disease or disorder selected
among pathologies of the
central nervous system (CNS), neurodegenerative diseases, autoimmune diseases,
type 2 diabetes,
insulin resistance, metabolic syndrome, cancers, such as respiratory tumors or
acute promyelocytic
leukemia, acquired immunodeficiency syndromes, cancerology, osteoporosis,
diseases linked to
oxidative stress, bipolar disorders, depression, and inflammatory disorders.
Metal ions in reverse micelle system formulated according to the invention are
preferably able to cross
the blood brain barrier. Consequently, they can be useful in the treatment of
central nervous sytem
(CNS) disorders, in particular genetic, tumoral, viral and/or degenerative
diseases in the CNS.
CA 02792136 2012-09-05
WO 2011/117333 15 PCT/EP2011/054511
A particular embodiment concerns a pharmaceutical composition as described
above, wherein the
metal ion is lithium, and that is used for the prevention, treatment or
improvement of the symptoms of
a disease or disorder selected among pathologies of the CNS and
neurodegenerative diseases.
A further particular embodiment concerns a pharmaceutical composition as
described above, wherein
the metal ion is vanadium, and that is used for the prevention, treatment or
improvement of the
symptoms of a disease or disorder selected among type 2 diabetes, insulin
resistance and metabolic
syndrome.
A further particular embodiment concerns a pharmaceutical composition as
described above, wherein
the metal ion is manganese, and that is used for the prevention, treatment or
improvement of the
symptoms of a disease or disorder selected among disorders linked to oxidative
stress.
A further particular embodiment concerns a pharmaceutical composition as
described above, wherein
the metal ion is arsenic, and that is used for the prevention, treatment or
improvement of the symptoms
of cancers, such as acute promyelocytic leukaemia.
A further particular embodiment concerns a pharmaceutical composition as
described above, wherein
the metal ion is strontium, and that is used for the prevention, treatment or
improvement of the
symptoms of osteoporosis.
"Subject" refers to an organism to which the metal ions of the invention can
be administered. The
subject may be a non-human animal, preferably a mammal. The preferred subject
is a human subject.
As used herein, the terms "mucosa" and "mucosal" refer to a mucous tissue such
as of the respiratory,
digestive, or genital tissue. ''Mucosal delivery", "mucosal administration"
and analogous terms as used
herein refer to the administration of a composition through a mucosal tissue.
"Mucosal delivery",
"mucosal administration" and analogous terms include, but are not limited to,
the delivery of a
composition through bronchi, gingival, lingual, nasal, oral, vaginal, rectal,
and gastro-intestinal
mucosal tissue.
In a preferred embodiment of the invention, the reverse micelle composition of
the invention is
mucosally administered as a capsule, a caplet, an aerosol, a spray, a solution
or a soft elastic gelatin
capsule. The compositions of the invention can for instance be introduced in
liquid form into capsules
which release their contents in the mouth or on any mucous tissue. Preferably,
the reverse micelle
compositions of the invention are administered to a mammal, more preferably a
human, to treat a
disease or disorder.
The following examples are intended to exemplify the operation of the present
invention but not to
limit its scope.
CA 02792136 2012-09-05
WO 2011/117333 16 PCT/EP2011/054511
DESCRIPTION OF THE FIGURES
Figure 1: Evaluation of the impact of the rate of incorporated water in
absence of lecithin on
diffraction curves (fig 1a) and size (fig 1b) of reverse micelles.
Figure 2: Evaluation of the impact of the rate of incorporated water in
presence of lecithin on
diffraction curves (fig 2a) and size (fig 2b) of reverse micelles.
Figure 3: Evaluation of the impact of the sterol origin on diffraction
curves of reverse micelles.
Figure 4: In vivo evaluation of lithium distribution in blood components
after administration of
lithium in reverse micelles folinulated with or without lecithin.
Figure 5: In vivo evaluation of efficacy of lithium in reverse micelles on
EAE clinical scores.
Figure 6: In vivo evaluation of efficacy of lithium in reverse micelles
on EAE axonal loss.
Figure 7: In vivo evaluation of efficacy of lithium in reverse micelles
on R6/2 motor
coordination (rotarod test).
Figure 8: In vivo evaluation of efficacy of lithium in reverse micelles
on R6/2 motor
performances (swimming tank test).
Figure 9: In vivo evaluation of efficacy of lithium in reverse micelles
on R6/2 cognitive
performances (swimming tank test).
Figure 10: In vivo evaluation of efficacy of lithium in reverse micelles
on survival of mice
innoculated with prion.
Figure 11: In vivo evaluation of efficacy of lithium in reverse micelles on
mice behavioural
model of depression (tail suspension test).
CA 02792136 2012-09-05
WO 2011/117333 17 PCT/EP2011/054511
EXAMPLES
Example 1: Evaluation of water incorporation impact on formation and size of
reverse micelles
in absence of lecithin
The aim of this study was to evaluate by X ray diffraction method and visual
determination the impact
of water content on the formation of thermodynamically stable microemulsions
and the size of reverse
micelles dispersed therein.
formulations of reverse micelles with different percentages of water were
prepared according to the
procedure below.
10 0.7 g of phytosterol were dissolved in 1.4 g of absolute ethanol by
magnetic stirring at 300 r/min for
minutes at 37 C. Glycerol monooleate was added thereto and magnetic stirring
was carried out at
500 r/min for 45 minutes at 37 C. Purified water was added to this oil mixture
and stirred between at
700 rpm for 30 minutes at 37 C to form "empty" reverse micelles.
The different formulations are summarized in the table below.
Sample Water content ("/0) Glycerol
monooleate Water
1 1 25.8g 0.3 g
2 2 25.5g 0.6g
3 3 25.2g 0.9 g
4 4 24.9g 1.2g
5 5 24.6g 1.5g
6 6 24.3g 1.8g
7 7 24.0g 2.1 g
8 8 23.7g 2.4g
9 9 23.4g 2.7g
10 10 23.1 g 3.0 g
"Empty" reverse micelles were prepared by increasing quantity of water from 1%
to 10% with
increment of 1% (the percentage of water is expressed by weight of water/total
volume of the
composition, density of 0.94). The percentage of absolute ethanol (5%) and
phytosterol (2.5%)
(weight/total weight of the composition) were unchanged for all these
products.
The formation of thermodynamically stable microemulsions was evaluated by the
visual determination
of their limpidity.
CA 02792136 2012-09-05
WO 2011/117333 18 PCT/EP2011/054511
Lattice parameters are obtained by X-ray diffraction and they are assumed to
correspond to the size of
reverse micelles of the invention. Samples were introduced in 1.5 mm diameter
glass capillaries and a
transmission configuration was used. A cupper rotating anode X-Ray source
(functioning at 4kW)
with a multilaycr focusing "Osmic" monochromator giving high flux (108
photons/sec) and punctual
collimation were employed. An "Image plate" 2D detector was used. Diffraction
curves were obtained
giving diffracted intensity as a function of the wave vector q. Diffracted
intensity was corrected by
exposition time, transmission and intensity background coming from diffusion
by an empty capillary.
Reverse micelle sizes were calculated with the formula: d = 2 rclqmax (q max
is the wave vector
corresponding to the maximal diffracted intensity).
Diffraction curve of 10 samples prepared according to above procedure are
shown in figure la, which
clearly demonstrates that between 1% and 6% of incorporated water, the qmax
value decreases when
the percentage of water increases. Figure lb shows that between 1% and 6% of
incorporated water, the
size of reverse micelles increases from 3.1 to 3.7 rim when the percentage of
water increases. In
contrast, from 7% of incorporated water, the size of reverse micelles stops
increasing.
Furthermore, the visual analysis shows that from 1 to 5 % of incorporated
water, the products are
limpid. From 6% of water, the products become more and more turbid.
These results clearly show that formulations formed in absence of lecithin are
unstable over a certain
amount of water (6%). They additionally show that the micelles formulated
without lecithin cannot
exceed a given size even when increasing the amount of water in the
formulation.
Example 2: Evaluation of water incorporation impact on formation and size of
reverse micelles
in presence of lecithin
The aim of this study was to evaluate by X ray diffraction method and visual
determination the impact
of water content on the formation of thermodynamically stable microemulsions
and the size of reverse
micelles dispersed therein in presence of increasing rate of lecithin.
3 formulations of reverse micelles with different percentages of water and
lecithin were prepared
according to the procedure below.
Commercially available lecithin was dissolved in 8.5 g absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 2.3 g of phytostcrol were added to
the mixture and stirred in
the same conditions. Glycerol monooleate was added thereto and magnetic
stirring was carried out at
500 r/min for 45 minutes at 37 C to form an oil mixture. Purified water was
added to the oil mixture
CA 02792136 2012-09-05
WO 2011/117333 19 PCT/EP2011/054511
and stirred at room temperature by magnetic stirring at 700 r/min for 30
minutes to form "empty"
reverse micelles.
The different formulations are summarized in the table below.
Sample Lecithin Glycerol monooleate Water Oil
mixture
11 0 g (0%) 79.3 g 20.4 mg (4%) 453.9 mg
12 9.4 g (10%) 64.8 g 45.0 mg (9%) 433.8 mg
13 14.1 g (15%) 57.0 g 60.0 mg (12%) 423.3 mg
"Empty" reverse micelles were prepared by varying quantity of water from 4%
(sample 11) to 12%
(sample 13) and lecithin from 0% (sample 11) to 15% (sample 13). Lecithin
content is calculated from
weight of lecithin/total weight of the composition and water content from
weight of water/total volume
of the composition (density of 0.94). The percentage of phytosterol was 2.5%
(weight of
phytosterol/total weight of the composition) and of absolute ethanol was 9%
(weight of absolute
ethanol/total weight of the composition) for all these samples.
The formation of thermodynamically stable microemulsions was evaluated by the
visual determination
of their limpidity.
The size of reverse micelles of these formulations was evaluated by X-ray
diffraction experiments as
described in example 1.
Diffraction curves of samples 11, 12, and 13 are shown in figure 2a which
clearly demonstrates that
the diffracted intensity increases and the qmax value decreases when the
percentage of lecithin
increases from 0 to 15%. Figure 2b demonstrates that the size of reverse
micelles increases from 3.1 to
4.5 nm when the percentage of lecithin increases from 0 to 15%. The visual
analysis shows that these
formulations are limpid.
Consequently, these experiments show that the addition of 15 % of lecithin
allows the formation of
thermodynamically stable microemulsions with reverse micelle size of 4.5 nm
and high percentages of
water (12%). Addition of lecithin thus solves the drawbacks of reverse
micelles formulated in absence
of lecithin described in example 1.
CA 02792136 2012-09-05
WO 2011/117333 20 PCT/EP2011/054511
Example 3: Reverse micelles according to the invention
The aim of this study was to evaluate by X ray diffraction method and visual
determination the
stability of a microemulsion according to the invention and the size of
reverse micelles dispersed
therein.
Sample A: 5.7 g of commercially available lecithin were dissolved in 8.5 g of
absolute ethanol by
magnetic stirring at 300 r/min for 10 minutes at room temperature. 2.4 g of
phytosterol were added to
the mixture and stirred in the same conditions. 68.6 g of glycerol monooleate
were added thereto and
magnetic stirring was carried out at 500 r/min for 1 hour at 37 C. 9.0 g of
purified water containing
148.7 mg of vanadium sulfate (30.0 mg of metal vanadium) were added to this
oil mixture and stirred
at room temperature at 700 r/min for 15 minutes to form reverse micelles
containing 300 itg metal
vanadium/ml (density of 0.94). The formulation contains 6% of lecithin.
Lecithin content is calculated from weight of lecithin/total weight of the
composition. The percentage
of water was 9% (weight of water/total volume of the composition), of
phytosterol was 2.5% (weight
of phytosterol/total weight of the composition) and of absolute ethanol was 9%
(weight of absolute
ethanol/total weight of the composition).
Visual analysis showed that the microemulsion formulated with 6% of lecithin
was limpid. The size of
reverse micelles of this formulation was determined by X-ray diffraction
experiments as described in
example 1 to be 4 nm.
Example 4: Evaluation of the impact of sterol origin on formation and size of
reverse micelles
The aim of this study was to evaluate by X ray diffraction method and visual
determination the impact
of the origin of the sterol (cholesterol or phytosterol) incorporated in the
formulation on the formation
of thermodynamically stable microemulsions and the size of reverse micelles
dispersed therein.
4 formulations of reverse micelles containing vanadium or "empty- with
phytosterol or cholesterol
were prepared according to the procedures below:
Sample B: 84.5 g of lecithin were dissolved in 141.0 g of absolute ethanol by
magnetic stirring at 150
r/min for 15 minutes at room temperature. 35.2 g of phytosterol were added to
the mixture and stirred
in the same conditions. 1074.3 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 200 r/min for 1 h and 20 minutes at 37 C. 75.0 g of purified
water containing 1.3 g of
vanadium sulfate (0.27 g of metal vanadium) were added to this oil mixture and
stirred at room
temperature at 240 r/min for 15 minutes to form reverse micelles containing
180 ug metal
vanadium/ml (density of 0.94).
CA 02792136 2012-09-05
WO 2011/117333 21 PCT/EP2011/054511
Sample 14: 75.0 g of purified watcr were added to of the oil mixture prepared
according to sample B
and stirred at room temperature at 240 r/min for 15 minutes to form "empty"
reverse micelles.
Sample C: 1.7 g of lecithin were dissolved in 2.8 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 0.7 g of cholesterol were added to
the mixture and stirred in
the same conditions. 21.5 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 0.5 g of purified water
containing 8.5 mg of vanadium
sulphate (1.8 mg of vanadium metal) were added to 8.9 g of this oil mixture
and stirred at room
temperature at 700 r/min for 15 minutes to form reverse micelles containing
180 jig metal
vanadium/ml (density of 0.94).
Sample 15: 0.5 g of purified water were added to 8.9 g of the oil mixture
prepared according to
sample C and stirred at room temperature at 700 r/min for 15 minutes to form
"empty" reverse
micelles.
Reverse micelles containing 180 jig metal vanadium/m1 (samples B and C) or
without metal (samples
14 and 15) were formulated with phytosterol or cholesterol according to the
above procedures. The
percentage of water was 5% (weight of water/total volume of the composition),
that of sterol was 2.5%
(weight of steroUtotal weight of the composition), that of lecithin was 6%
(weight of lecithin/total
weight of the composition) and that of absolute ethanol was 10% (weight of
absolute ethanol/total
weight of the composition) for all these samples.
The formation of thermodynamically stable microemulsions was evaluated by the
visual determination
of their limpidity.
The size of reverse micelles of these formulations was evaluated by X-ray
diffraction experiments as
described in example 1.
Diffraction curve of samples B, C, 14 and 15 are shown in figure 3 which
demonstrates that the qmax
values are the same for all the formulations. Then, the reverse micelle size
is calculated at 3.3 nm.
Furthermore, the visual observation of these products shows that all samples
are limpid.
These experiments show that neither the sterol origin (phytosterol or
cholesterol) nor the addition of
vanadium at 180 gg/m1 has an impact on the formation of thermodynamically
stable microcmulsions,
nor on the size of reverse micelles dispersed therein.
CA 02792136 2012-09-05
WO 2011/117333 22 PCT/EP2011/054511
Example 5: Evaluation of in vivo blood repartition of lithium formulated in
reverse micelles in
presence and absence of lecithin
The aim of this study was to evaluate the repartition in blood components
(plasma versus blood cells)
of lithium formulated in 2 different reverse micelles formulations prepared
according to procedures
below (samples D and E) when delivered by rectal route.
Sample D: 1.4 g of phytosterol were dissolved in 4.0 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 48.9 g of glycerol monooleate were
added thereto and
magnetic stirring was carried out at 500 r/min for 45 minutes at 37 C. 2.4 g
of purified water
containing 25.7 mg of lithium carbonate (4.8 mg of metal lithium) were added
to this oil mixture and
stirred at room temperature at 700 r/min for 15 minutes to form reverse
micelles containing 80 ps
metal lithium/ml (density of 0.94).
Sample E: 3.4 g of lecithin were dissolved in 5.1 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 1.5 g of phytosterol were added to
the mixture and stirred in
the same conditions. 41.1 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 5.4 g of purified water
containing 65.6 mg of lithium
citrate (4.8 mg of metal lithium) were added to this oil mixture and stirred
at room temperature at 700
r/min for 15 minutes to form reverse micelles containing 80 lug metal
lithium/ml (density of 0.94).
Administered products:
- Sample D: reverse micelles prepared according to above procedure at 80 lug
metal lithium/ml,
.. delivered at lml/kg by rectal route
- Sample E: reverse micelles prepared according to above procedure at 80 jig
metal lithium/ml,
delivered at lml/kg by rectal route
Spragues Dawley rats, 5 rats per group, were administered with 160 ps metal
lithium/kg (80 lag/kg
twice, 15 minutes interval) by rectal route with 2 formulations of lithium in
reverse micelles (samples
D and E). These products were administered slowly with a pipette into the
lower rectum, immediately
after the anal sphincter.
Animals were sacrificed 2 hours after the last treatment and blood samples
were collected by intra-
cardiac puncture. Centrifugation was performed at 4500 r/m for 5 minutes to
separate plasma from
blood cells.
Lithium concentration in plasma and blood cells was determined by Inductively
Coupled Plasma Mass
Spectrometry (ICPMS).
CA 02792136 2012-09-05
WO 2011/117333 23 PCT/EP2011/054511
Results are shown in figure 4 which demonstrates that the addition of lecithin
in reverse micelles of
sample E did not decrease the delivery of lithium and did not change the
repartition of lithium
between plasma and blood cells. Reverse micelles according to the invention
are thus as efficient as
those not containing lecithin for delivery of low quantities of metal ions.
They additionally allow
delivery of greater amounts of metal ions than reverse micelles without
lecithin.
Example 6: Evaluation of in vivo efficacy of reverse micelles formulated with
lithium in EAE
mice model of Multiple Sclerosis
Multiple Sclerosis is the most common autoimmune inflammatory disease in the
CNS. It is
characterized by immune mediated demyelinisation and neurodegeneration of the
CNS.
Experimental autoimmune encephalomyelitis (EAE) is a standard widely used
experimental model of
the clinical, immunological and neuropathological features of Multiple
Sclerosis.
The aim of this study was to evaluate the efficacy of a pre-treatment with
reverse micelles formulated
with lithium according to procedures below (samples F and 16) in a chronic EAE
model induced in
mice.
Sample F: 3.4 g of lecithin were dissolved in 5.0 g absolute ethanol by
magnetic stirring at 300 r/min
for 10 minutes at room temperature. 1.4 g of phytosterol were added to the
mixture and stirred in the
same conditions. 41.2 g of glycerol monooleate were added thereto and magnetic
stirring was carried
out at 500 r/min for 45 minutes at 37 C. 5.4 g of water containing 32.7 mg of
lithium citrate (2.4 mg
of metal lithium) were added to this oil mixture and stirred at room
temperature at 700 r/min for 15
minutes to form reverse micelles containing at 40 lug metal lithium/ml
(density of 0.94).
Sample 16: 1.7 g of lecithin were dissolved in 2.5 g absolute ethanol by
magnetic stirring at 300 r/min
for 10 minutes at room temperature. 0.7 g of phytosterol were added to the
mixture and stirred in the
same conditions. 20.6 g of glycerol monooleate were added thereto and magnetic
stirring was carried
out at 500 r/min for 45 minutes at 37 C. 2.7 g of water were added to this oil
mixture and stirred at
room temperature at 700 r/min for 15 minutes to form "empty" reverse micelles.
Administered products:
- Sample F: reverse micelles prepared according to above procedure at 40 lug
metal lithium/ml,
delivered at lmlikg by rectal route from day 0 to day 50
- Sample 16: "empty" reverse micelles prepared according to above procedure,
delivered at lml/kg by
rectal route from day 0 to day 50
CA 02792136 2012-09-05
WO 2011/117333 24 PCT/EP2011/054511
To induce EAE, C57bV6 were injected subcutaneously on days 0 and 7 with 150
lug of MOG peptide
emulsified in complete Freund's adjuvant (Difco laboratories) supplemented
with Mycobacterium
tuberculosis H37 RA (Difco laboratories) at a final concentration of 5 mg/ml.
In addition, on days 0
and 2 post-immunization (p.i.), mice were given 500 ng pertussis toxin (Sigma
Aldrich Corporation)
intraperitonally.
These mice (4 mice per group) were treated 5 days a week by rectal route with
lithium formulated in
reverse micelles (sample F) from day 0 to day 50 post immunization. Sample F
at 40 jig metal
lithium/kg was delivered slowly with a pipette into the lower rectum,
immediately after the anal
sphincter. Mice treated with "empty" reverse micelles (sample 16) in the same
conditions (4 mice per
group) were used as control.
Animals were weighed and scored for clinical signs of disease from day 10 post-
immunization until
day 50 (week-ends excluded). Clinical assessment of EAE was performed daily
according to the
following criteria: 0 = no disease signs, 1 = tail weakness, 2 = tail
paralysis, 3 = incomplete paralysis
of one or two hind legs, 4 = complete hind limb paralysis, 5 = moribund, 6 =
death.
Animals were sacrificed on day 50 and spinal cords were harvested and frozen.
Quantification of axonal loss was performed on frozen spinal cord after
neurofilament
immunostaining. Cryostated sections of 14p,m were incubated firstly with an
antibody directed against
the 200 kDa neutrofilament protein (Serotec). They were incubated after with a
secondary antibody
labelled with biotin (Vector laboratories) and after with streptavidin-
alexafluor (Molecular Probes).
The axonal density was determined by visualisation of the ncurofilament
immunostaining using a
fluorescent microscope (Zeiss Axioplan II).
Results of clinical scores are shown in figure 5 which demonstrates that
lithium in reverse micelles
formulation containing lecithin (sample F) is effective at preventing the
apparition of clinical signs
during the acute phase of the disease and facilitates partial recovery during
the chronic phase of the
disease. In contrast "empty" reverse micelles are ineffective at decreasing
clinical score (sample 16).
These results are confirmed by immunostaining assays presented in figure 6
which demonstrates that
only the treatment with lithium in reverse micelles (sample F) prevents the
axonal loss in spinal cord
of EAE induced mice.
CA 02792136 2012-09-05
WO 2011/117333 25 PCT/EP2011/054511
Example 7: Evaluation of in vivo efficacy of reverse micelles formulated with
lithium in the R6/2
mice model of Huntington disease
Huntington disease (HD) is an inherited fatal neurologic disorder caused by an
expansion of a CAG
repeat in exon 1 of the huntingtin gene. The selective loss of a subset of
brain cells (neurons) involves
psychiatric, motor and cognitive disturbances.
R6/2 mice (Jackson Laboratory) are a transgenic model widely used as
Huntington's disease model.
They express human HD gene carrying approximately 120 +1- 5 (CAG) repeat
expansions. Transgenic
mice exhibit a progressive neurological phenotype that mimics many of the
features of HD, including
deficits of motor coordination, altered locomotor activity, impaired cognitive
performance and
seizures.
The aim of this study was to evaluate by a standardized battery of analysis
the neuroprotective effect
of lithium formulated in reverse micelles according to procedures below
(samples G and 11) in R6/2
mice compared to unformulated lithium administered by oral route. Motor
coordination and balance
were evaluated by rotarod test and swimming tank test. Cognitive performances
were evaluated by
swimming tank test.
Sample G: 1.0 g of phytosterol were dissolved in 3.0 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 36.5 g of glycerol monooleate were
added thereto and
magnetic stirring was carried out at 500 r/min for 45 minutes at 37 C. 1.8 g
of purified water
containing 9.7 mg of lithium carbonate (1.8 mg of metal lithium) were added to
this oil mixture and
stirred at room temperature at 700 r/min for 15 minutes to form reverse
micelles containing 40 jig
metal lithiumlml (density of 0.94).
Sample H: 9.4 g of lecithin were dissolved in 8.5 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 2.3 g of phytosterol were added to
the mixture and stirred in
the same conditions. 64.8 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 4.0 g of purified water
containing 24.3 mg of lithium
citrate (1.8 mg of metal lithium) were added to 38.2 g of this oil mixture and
stirred at room
temperature at 700 r/min for 15 minutes to form reverse micelles containing 40
jig metal lithium/ml
(density of 0.94).
Sample 17: 4.0 g of purified water were added to 38.2 g of the oil mixture
prepared according to
sample H and stirred at room temperature at 700 r/min for 15 minutes to form
"empty" reverse
micelles.
Administered products:
CA 02792136 2012-09-05
WO 2011/117333 26 PCT/EP2011/054511
- Sample G: reverse micelles prepared according to procedure above at 40
lug metal lithium/ml,
delivered at lml/kg/d by rectal route for at least 8 weeks
- Sample H: reverse micelles prepared according to procedure above at 40
ttg metal lithiumml,
delivered at lml/kg/d by rectal route for at least 8 weeks
- Sample 17: "empty" reverse micelles prepared according to procedure above,
delivered at lml/kg by
rectal route for at least 8 weeks
- Unformulated lithium: lithium in solution at 3.2 mg metal lithium/ml,
delivered at 5 ml/kg/d by oral
route (gavage) for at least 8 weeks
As described below, R6/2 at 8-9 weeks old (apparition of the first clinical
signs) were treated 5 days a
week for at least 8 weeks with lithium in solution (group 4, 10 mice per group
respectively) or
formulated in reverse micelles (samples G and H). Lithium in solution was
delivered by gavage at 16
mg metal lithium/kg using a plastic syringe fitted with a metal curved gavage
tube. Samples G and H
at 40 lug metal lithium/kg were delivered slowly with a pipette into the lower
rectum, immediately
after the anal sphincter (groups 1 and 2, 10 and 9 mice per group). R6/2 mice
and wild type mice
treated in the same conditions with -empty" reverse micelles (sample 17)
(group 3 and 5, 8 and 6 mice
per group) were used as control.
Rotarod tests were performed before and during the 4th and 6th week of
treatment using a Rota Rod
apparatus (UGO Basile 47600, rotating rod diameter 3 cm). After an acclimation
test of 15 minutes,
mice performed 2 trials at 5 rpm. The latency at which each mouse falls of the
rod was recorded.
Swimming tests were performed using a tank filled to a depth of 20 cm with
water and a visible escape
platform located at the end of the tank side. During the 4th week of
treatment, the latency to reach the
platform and the swimming speed were recorded 5 times per day during 5
consecutive days.
Results of rotarod test are shown in figure 7 which clearly demonstrates that
both formulations of
metal lithium in reverse micelles (samples G and H) maintain motor
coordination of R6/2 mice.
Furthermore, the effect of sample H formulated with lecithin administered at a
dosage of 40 jig/kg was
greater than those obtained with lithium by oral gavage at 16 mg/kg. in
contrast, the treatment with
reverse micelles containing no metal (sample 17) was ineffective at
maintaining motor coordination of
R6/2 mice.
Results of swimming speed shown in figure 8 confirm that the R6/2 mice treated
with lithium in both
formulations of reverse micelles (samples G and H) have better motor
performances than R6/2 mice
treated with lithium by oral gavage at 16 mg/kg or with reverse micelles
containing no metal (sample
17).
CA 02792136 2012-09-05
WO 2011/117333 27 PCT/EP2011/054511
Results of cognitive performance are shown in figure 9 which clearly
demonstrate that both
formulations of metal lithium in reverse micelles (samples G and H) maintain
the capacity of R6/2 to
learn a simple task : choose the good direction to reach the platfoini. In
contrast, reverse micelles
containing no metal (sample 17) are ineffective at maintaining cognitive
performances.
.. Reverse micelles according to the invention are thus as efficient as those
not containing lecithin for
delivery of low quantities of metal ions. They additionally allow delivery of
greater amounts of metal
ions than reverse micelles without lecithin.
Mouse Delivered Delivered
Animal
Groups Treatment dose volume
strain Number (iug/kg/d) (ml/kg/d)
1 10 Sample G 40 1
2 9 Sample H 40 1
R6/2
3 8 Sample 17 0 1
4 10 Lithium solution 16000 5
Wild
5 6 Sample 17 0 1
type
Example 8: Formulation of reverse micelles with high concentration of lithium
The aim of this study was to formulate lithium in reverse micelles at 600
ttg/m1 according to the
invention.
Sample I: 6.6 g of lecithin were dissolved in 5.9 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 1.6 g of phytostcrol were added to
the mixture and stirred in
the same conditions. 45.3 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 6.3 g of purified water
containing 567.7 mg of lithium
citrate (41.9 mg of metal lithium) were added to this oil mixture and stirred
at room temperature at 700
r/min for 15 minutes to form reverse micelles containing 600 gg metal
lithium/ml (density of 0.94).
The formation of thermodynamically stable microemulsion according to the
procedure above was
evaluated by the visual determination of its limpidity after 3 months at 40 C.
This experiment shows that the addition of lecithin at 10% allows the
formation of a limpid
thermodynamically stable microcmulsion with 600 Kg/m1 of metal lithium.
CA 02792136 2012-09-05
WO 2011/117333 28 PCT/EP2011/054511
Example 9: Evaluation of in vivo efficacy of reverse micelles formulated with
lithium in a mice
model of prion disease
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a
family of fatal and rare
progressive neurodegenerative disorders caused by an infectious agent (Prion)
composed of protein of
misfolded form. This agent is able to induce abnormal folding of normal
cellular prion proteins in the
brain, leading to brain damage (neuronal loss,...) and associated symptoms
(dementia,...).
C57b1/6J mice intracerebrally inoculated with brain homogenates infected with
ME7 prion typically
die between 165 and 175 days after innoculation. The disease is characterised
by vacuolisation and
neuronal loss, typically with a bilateral, symmetrical distribution as well as
asctrocyte proliferation
and prion protein accumulation.
The aim of this study was to evaluate the efficacy of treatment with reverse
micelles formulated with
lithium according to procedure below (sample J) on survival of mice infected
with prion compared to
unformulatcd lithium administered by oral route at higher dose.
Sample J: 23.5 g of lecithin were dissolved in 21.2 g of absolute ethanol by
magnetic stirring at 300
r/min for 15 minutes at room temperature. 5.9 g of phytosterol were added to
the mixture and stirred in
the same conditions. 162.0 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 10.8 g of purified water
containing 259.0 mg of
lithium citrate (19.2 mg of metal lithium) were added to 102.0 g of this oil
mixture and stirred at room
temperature at 700 r/min for 30 minutes to form reverse micelles containing
160 !Lig metal lithium/ml
(density of 0.94).
Sample 18: 10.8 g of purified water were added to 102.0 g of the oil mixture
prepared according to
sample J and stirred at room temperature at 700 r/min for 30 minutes to form
"empty" reverse
micelles.
Administered products:
- Sample J: reverse micelles prepared according to procedure above at 160
lig metal lithium/ml,
delivered at lml/kg/d by rectal route from 90 days after inoculation until
death
- Sample 18: "empty" reverse micelles prepared according to procedure
above, delivered at lml/kg by
rectal route from 90 days after inoculation until death
CA 02792136 2012-09-05
WO 2011/117333 29 PCT/EP2011/054511
- Unformulatcd lithium: lithium in solution at 3.2 mg metal lithiumiml,
delivered at 5 ml/kg/d by oral
route (gavage) from 90 days after inoculation until death
20 1.t1 of brain homogenates with 1% of ME7 prion were inoculated under
general anaesthesia in brain
of 5 weeks old C57b1/6 mice to induce disease. These mice were treated 5 days
a week (week-ends
excluded) with lithium in solution (14 mice per group) or formulated in
reverse micelles (sample J)
(14 mice per group) from 90 days after inoculation (at the post symptomatic
phase) until death.
Lithium in solution was delivered by gavage at 16 mg metal lithium/kg using a
plastic syringe fitted
with a metal curved gavage tube. Sample J at 160 lug metal lithium/kg was
delivered slowly with a
pipette into the lower rectum, immediately after the anal sphincter. Prion
innoculated mice treated in
the same conditions with "empty" reverse micelles (sample 18) (10 mice per
group) were used as
control.
Results of survival arc shown in figure 10 which clearly demonstrates that
treatment with lithium in
solution at 16 mg/kg or formulated in reverse micelles at 160 gg/kg (sample J)
increase survival of
prion infected mice compared to the treatment with reverse micelles containing
no metal (sample 18).
This experiment shows that, with an equivalent efficacy, the formulation in
reverse micelles according
to the invention affords a lithium dose decrease by 100 times compared to the
dose of lithium in
solution.
Example 10: Evaluation of in vivo efficacy of reverse micelles formulated with
lithium in a
bihavioural mice model of depression
Bipolar disorder is a psychiatric disease describe as a mood disorder. It is
defined by the alternation of
mania and depression episodes. The treatment to stabilize mood is based on
administration of high
doses of lithium which has acute antimanic and antidepressant effects and long
term prophylactic
effects.
The aim of this study was to evaluate the efficacy of a pre-treatment with
reverse micelles formulated
with lithium according to procedure below (sample K) on a standard widely used
behavioural mice
model of depression (tail suspension test) compared to unformulated lithium
administered by oral
route at higher dose.
Sample K: 28.2 g of lecithin were dissolved in 24.5 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 7.0 g of phytosterol were added to
the mixture and stirred in
the same conditions. 194.4 g of glycerol monoolcatc were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 7.2 g of purified water
containing 161.6 mg of lithium
citrate (12.0 mg of metal lithium) were added to 68.0 g of this oil mixture
and stirred at room
CA 02792136 2012-09-05
WO 2011/117333 30 PCT/EP2011/054511
temperature at 700 r/min for 15 minutes to form reverse micelles containing
150 lug metal lithium/ml
(density of 0.94).
Sample 19: 7.2 g of purified water were added to 68.0 g of the oil mixture
prepared according to
sample K and stirred at room temperature at 700 r/min for 15 minutes to form
"empty" reverse
micelles.
Administered products:
- Sample K: reverse micelles prepared according to procedure above at 150
lig metal lithium/ml,
delivered at lml/kg/d by rectal route during 4 weeks before the test
- Sample 19: "empty" reverse micelles prepared according to procedure
above, delivered at lml/kg by
rectal route during 4 weeks before the test
- Unformulated lithium: lithium in solution at 3.2 mg metal lithium/ml,
delivered at 5 ml/kg/d by oral
route (gavage) during 4 weeks before the test
C57b1/6 mice were treated 5 days a week (week-ends excluded) during 4 weeks
with lithium in
solution (12 mice per group) or formulated in reverse micelles (sample K) (12
mice per group).
Lithium in solution was delivered by gavage at 16 mg metal lithium/kg using a
plastic syringe fitted
with a metal curved gavage tube. Sample K at 150 lug metal lithium/kg was
delivered slowly with a
pipette into the lower rectum, immediately after the anal sphincter. Mice
treated in the same conditions
with "empty" reverse micelles (sample 19) (12 mice per group) were used as
control.
After a 4-week treatment, mice were tails suspended during 6 min and
depression-like behaviour was
characterized by time spent to be immobile. The total time of immobility was
recorded.
Results of tail suspension test are shown in figure 11 which clearly
demonstrates that times of
immobility of mice treated with lithium in solution at 16 mg/kg or formulated
in reverse micelles at
150 jig/kg (sample K) are significantly lower than the time of immobility of
mice treated with reverse
micelles containing no metal (sample 19).
This experiment shows that, the depression-like behaviour induced by tail
suspension test is alleviated
by both lithium treatment. Furthermore, the formulation of lithium in reverse
micelles according to the
invention affords a dose decrease by 100 times compared to the dose of lithium
in solution.
CA 02792136 2012-09-05
WO 2011/117333 31 PCT/EP2011/054511
Example 11: Formulation of reverse micelles with high concentration of lithium
The aim of this study was to formulate lithium in reverse micelles at 1200
fig/m1 according to the
invention.
Sample L: 569.9 g of lecithin were dissolved in 342.1 g of absolute ethanol by
magnetic stirring at
100 r/min for 15 minutes at room temperature. 95.2 g of phytosterol were added
to the mixture and
stin-ed in the same conditions. 2313.4 g of glycerol monooleate were added
thereto and magnetic
stirring was carried out at 200 r/min for 120 minutes at 37 C. 480.0 g of
purified water containing
6478.1 mg of lithium citrate (480.0 mg of metal lithium) were added to this
oil mixture and stirred at
room temperature at 200 r/min for 15 minutes to form reverse micelles
containing 1200 ug metal
lithium/ml (density of 0.95).
The formation of thermodynamically stable microemulsion according to the
procedure above was
evaluated by the visual determination of its limpidity.
This experiment shows that the addition of lecithin at 15% allows the
formation of a limpid
thermodynamically stable microemulsion with 1200 [tg/m1 of metal lithium.
